OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Immunology Immunotherapy is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Pembrolizumab and atezolizumab in triple-negative breast cancer	136
Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors	123
An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma	97
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis	91
Chemotherapy: a double-edged sword in cancer treatment	89
Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma	86
Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC	82
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy	72
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives	72
Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer	71
Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients	70
Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma	69
Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC)	63
OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway	63
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity	63
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells	61
The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer	60
ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer	60
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort	56
PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade	55
Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy	55
Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models	53
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%	52
A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment	51
Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer	50

Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma	45
Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab	44
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial	43
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disea	43
Expression of the immune checkpoint VISTA in breast cancer	42
Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase	42
Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma	42
Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma	42
Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis	41
Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer	39
Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors	39
Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors	38
Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers	38
Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study	38
Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer	38